Immunoterapia di 1 linea Evidenze e Prospettive Future
|
|
- Thomasina Terry
- 5 years ago
- Views:
Transcription
1 Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018
2 Disclosures Advisory Boards/Honoraria/Speakers fee/consultant for: Astra-Zeneca, Eli-Lilly, Boeringher Ingelheim, BMS, Roche Research Support/Grants from: A.I.R.C. (Associazione Italiana Ricerca sul Cancro) I.A.S.L.C. (International Association for the Study of Lung Cancer) Fondazione Cariverona Open Innovation Astra-Zeneca
3 Proportion Alive Hypothetical Goals of Immunotherapy Immunotherapy monotherapy Long-term survival Control Chemotherapy/TKI Time from Treatment TKI = tyrosine kinase inhibitor. Adapted from Sharma P, Allison JP. Cell. 2015;161(2): Horn, WCLC 2018
4 1 st Line Treatment Landscape in NSCLC Today Wild-Type Non-squamous Squamous PD-L1 0-49% PD-L1 50% KN 024 pembro PD-L1 50% PD-L1 0-49% Platinumbased CT PD-L1 50% Platinumbased CT WILD-TYPE for oncogene-addicted alterations Pembrolizumab
5 Wild-Type 1 st Line Treatment Landscape in NSCLC What s New? Non-squamous Squamous PD-L1 0-49% PD-L1 50% KN 024 pembro PD-L1 50% PD-L1 0-49% Platinumbased CT IMpower 132 atezo + platinum-pem KN 189 pembro + platinum-pem IMpower 130 atezo + carbo-nab-txl IMpower 150 atezo + beva carbo-txl KN 042 pembro CM 227 nivo + ipi CM 227 nivo + platinum-based CT KN 407 pembro + carbo-tax IMpower 131 atezo + carbo-nab-txl Platinumbased CT
6 Immuno alone? Immuno or chemo + immuno? Antiangiogenic? Patients characteristics? Age-PS? Histology? Oncogeneaddicted? Sequence? Steroids? Antibiotics? PD-L1 or TMB? Immunological profile Toxicity? Molecular background
7 The invasion of clinical trials MONOTHERAPY CHEMOTHERAPY COMBINATIONS IT + IT KN-024 Pembro mono CM026 Nivo mono KN-042 Pembro mono IM150 Atezo + bev + carbo + pac IM132 Atezo + cis/carbo + pem IM130 Atezo + carbo + nab-pac KN-189 Pembro + cis/carbo + pem IM131 Atezo + carbo + tax KN-407 Pembro + carbo + tax CM227 Nivo + chemo CM227 Nivo mono or + ipi or + chemo Non-squamous & squamous Non-squamous Squamous Non-squamous & squamous TPS 50% TPS 1% All PD-L1 All PD-L1 PD-L1 <1% TMB?
8 O S, % Updated Analysis of KEYNOTE-024: Pembro in PD-L1 high ( 50%) months follow-up 70.3% 54.8% 51.5% 34.5% Events, n HR (95% CI) Pembrolizumab a Chemotherapy 96 ( ) P = b Median (95% CI) 30.0 mo (18.3 mo NR) 14.2 mo (9.8 mo 19.0 mo) Control Arm: 63% of discontinued pts received IO N o. a t ris k T im e, m o n th s P e m b r o C h e m o Censoring rate (55% of pts with event) Brahmer J et al, WCLC 2017
9 IO single agent versus platinum-based CT: low PD-L1 expression KEYNOTE 042: Study design CheckMate 026: Study design Key eligibility criteria: Stage IV or recurrent NSCLC No prior systemic therapy for advanced disease No EGFR/ALK mutations sensitive to available targeted inhibitor therapy 1% PD-L1 expression a CNS metastases permitted if adequately treated at least 2 weeks prior to randomization Randomize 1:1 Nivolumab 3 mg/kg IV Q2W n = 271 Chemotherapy (histology dependent) b Maximum of 6 cycles n = 270 Tumor scans Q6W until wk 48 then Q12W Disease progression Disease progression or unacceptable toxicity Crossover nivolumab c (optional) Stratification factors at randomization: PD-L1 expression (<5% vs 5%) a Histology (squamous vs non-squamous) Primary endpoint: PFS ( 5% PD-L1+) d Secondary endpoints: PFS ( 1% PD-L1+) d OS ORR d Lopes G, ASCO 2018; Carbone, NEJM 2017
10 Lopes G, ASCO 2018; Carbone, NEJM 2017 IO single agent versus platinum-based CT: OS PD-L1 low expression KEYNOTE 042 CheckMate 026
11 Proportion Alive Hypothetical Goals of Immunotherapy in Combination Mono immunotherapy Combination ICI Long-term survival Control Chemotherapy/TKI Time from Treatment Horn, WCLC 2018
12 Chemotherapy No treatment Chemotherapy Does Tumor cell killing by cytotoxic chemotherapy expose immune system to high levels of tumor cell antigens? Weak antigen presentation Weak PD-1/PD-L1 expression Immunotherapy High immunosuppressive cytokines Weak antigen presentation Low PD-1/PD-L1 expression Low T-cell infiltration T-cell infiltration High immunosuppressive cytokines Antigen presentation PD-L1 expression PD-L1 expression Antigen presentation Potential impaired T- cell function Immunosuppressive cytokines T-cell infiltration Regulatory T-cells Potential impaired T- cell function Immunosuppressive cytokines Regulatory T-cells Tumor cell Apoptotic tumor Antigen-specific T-cell Regulatory Apoptotic Apoptotic antigen- Neutrophil Macrophage MHC1Danger signal PD-1 / PD-L1 Anti-PD-1 Cytokines Immunosuppressive cell T-cell T-cell T-cell specific T-cell or CTLA-4 Anti-PD-L1 cytokines. Horn, WCLC 2018
13 The invasion of clinical trials MONOTHERAPY CHEMOTHERAPY COMBINATIONS IT + IT KN-024 Pembro mono CM026 Nivo mono KN-042 Pembro mono IM150 Atezo + bev + carbo + pac IM132 Atezo + cis/carbo + pem IM130 Atezo + carbo + nab-pac KN-189 Pembro + cis/carbo + pem IM131 Atezo + carbo + tax KN-407 Pembro + carbo + tax CM227 Nivo + chemo CM227 Nivo mono or + ipi or + chemo Non-squamous & squamous Non-squamous Squamous Non-squamous & squamous TPS 50% TPS 1% All PD-L1 All PD-L1 PD-L1 <1% TMB?
14 Non-Squamous NSCLC [KEYNOTE-021G] Overall Survival, % No. at risk Median (95% CI) NR (22.8 NR) 20.9 (14.9 NR) 18.7 months follow-up 77% 69% 70% 56% Time, months Censoring rate (42% of pts with event) Median Follow-Up: 18.7 mo Events, n/n HR (95% CI) Pembro + PC 20/60 a 0.59 PC alone 31/63a ( ) P = 0.03 b Control Arm: 75% of discontinued pts received IO Borghaei, WCLC 2017
15 Non-Squamous NSCLC [KEYNOTE-189] Key Eligibility Criteria Untreated stage IV nonsquamous NSCLC No sensitizing EGFR or ALK alteration ECOG PS 0 or 1 Provision of a sample for PD-L1 assessment No symptomatic brain metastases No pneumonitis requiring systemic steroids R (2:1) N = 410 N = 206 Pembrolizumab 200 mg + Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 OR Cisplatin 75 mg/m 2 Q3W for 4 cycles Placebo (normal saline) + Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 OR Cisplatin 75 mg/m 2 Q3W for 4 cycles Pembrolizumab 200 mg Q3W for up to 31 cycles + Pemetrexed 500 mg/m 2 Q3W Placebo (normal saline) for up to 31 cycles + Pemetrexed 500 mg/m 2 Q3W Stratification Factors PD-L1 expression (TPS a <1% vs 1%) Platinum (cisplatin vs carboplatin) Smoking history (never vs former/current) Pembrolizumab 200 mg Q3W for up to 35 cycles PD b (616 patients) Gandhi, NEJM 2018
16 O S, % P F S, % Non-Squamous NSCLC [KEYNOTE-189] N o. a t R is k OS: HR 0.49 [95% CI: ]; p < M o n th s 12-mo rate 69.2% 49.4% Median (95% CI) NR (NE-NE) 11.3 mo ( ) PFS: HR 0.52 [95% CI: ]; p < mo rate 34.1% 17.3% Median (95% CI) 8.8 mo ( ) 4.9 mo ( ) N o. a t R is k M o n th s Subgroup Analyses OS: Positive across all subgroups PFS: Positive across all subgroups except for PD-L1 TPS <1% Gandhi, NEJM 2018
17 Non-Squamous NSCLC [KEYNOTE-189] OS TPS <1% TPS 1-49% TPS 50% TPS <1% TPS 1-49% TPS 50% PFS HR 0.59 ( ) HR 0.55 ( ) HR 0.42 ( ) HR 0.75 ( ) HR 0.55 ( ) HR 0.36 ( ) Gandhi, NEJM 2018
18 Non-Squamous NSCLC [IMpower132] Papadimitrakopoulou, WCLC 2018 Co-primary endpoints: INV-assessed PFS and OS Secondary endpoints: INV-assessed ORR and DOR, PRO and safety measures Exploratory analyses: clinical and biomarker subgroup analyses Biomarker-evaluable tissue not mandatory for enrolment (was available from 60% of patients)
19 Non-Squamous NSCLC [IMpower132] Papadimitrakopoulou, WCLC 2018 PFS OS
20 Barlesi F, ESMO 2018 Non-Squamous NSCLC [IMpower132] PFS benefit in key subgroups 75-84y HR % never smoker
21 Non-Squamous NSCLC [IMpower130] Cappuzzo F, ESMO 2018
22 Non-Squamous NSCLC [IMpower130] ITT Cappuzzo F, ESMO 2018 PFS OS
23 Non-Squamous NSCLC [IMpower150] Socinski M, ASCO 2018 Co-Primary Endpoint Analysis
24 Non-Squamous NSCLC [IMpower150] Socinski M, ASCO 2018 PFS (B vs C) OS (B vs C)
25 The invasion of clinical trials MONOTHERAPY CHEMOTHERAPY COMBINATIONS IT + IT KN-024 Pembro mono CM026 Nivo mono KN-042 Pembro mono IM150 Atezo + bev + carbo + pac IM132 Atezo + cis/carbo + pem IM130 Atezo + carbo + nab-pac KN-189 Pembro + cis/carbo + pem IM131 Atezo + carbo + tax KN-407 Pembro + carbo + tax CM227 Nivo + chemo CM227 Nivo mono or + ipi or + chemo Non-squamous & squamous Non-squamous Squamous Non-squamous & squamous TPS 50% TPS 1% All PD-L1 All PD-L1 PD-L1 <1% TMB?
26 Squamous NSCLC [KEYNOTE-407] Paz-Ares L, ASCO 2018
27 Squamous NSCLC [KEYNOTE-407] Paz-Ares L, ASCO 2018
28 Squamous NSCLC [KEYNOTE-407] Halmos, WCLC 2018
29 KN 407: PROs Results Mazieres, ESMO 2018
30 Squamous NSCLC [IMpower131] Jotte R, ASCO 2018
31 Squamous NSCLC [IMpower131] Jotte R, ASCO 2018 PFS (B vs C) OS (B vs C) In PD-L1 low (TC1/2 or IC1/2) OS has an opposite trend
32 The invasion of clinical trials MONOTHERAPY CHEMOTHERAPY COMBINATIONS IT + IT KN-024 Pembro mono CM026 Nivo mono KN-042 Pembro mono IM150 Atezo + bev + carbo + pac IM132 Atezo + cis/carbo + pem IM130 Atezo + carbo + nab-pac KN-189 Pembro + cis/carbo + pem IM131 Atezo + carbo + tax KN-407 Pembro + carbo + tax CM227 Nivo + chemo CM227 Nivo mono or + ipi or + chemo Non-squamous & squamous Non-squamous Squamous Non-squamous & squamous TPS 50% TPS 1% All PD-L1 All PD-L1 PD-L1 <1% TMB?
33 Hellman, AACR 2017 CheckMate-227 N = 1189 Nivolumab 3 mg/kg Q2W Ipilimumab 1 mg/kg Q6W n = 396 Patients for PD-L1 co-primary analysis Nivolumab + ipilimumab n = 396 1% PD-L1 expression R 1:1:1 Histology-based chemotherapy b n = 397 Chemotherapy b n = 397 Key Eligibility Criteria Stage IV or recurrent NSCLC No prior systemic therapy No known sensitizing EGFR/ALK alterations ECOG PS 0 1 Nivolumab 240 mg Q2W n = 396 Patients for TMB co-primary analysis c Nivolumab + ipilimumab n = 139 Chemotherapy b n = 160 Stratified by SQ vs NSQ N = 550 <1% PD-L1 expression R 1:1:1 Nivolumab 3 mg/kg Q2W Ipilimumab 1 mg/kg Q6W n = 187 Histology-based chemotherapy b n = 186 Nivolumab 360 mg Q3W + histology-based chemotherapy b n = 177 Co-primary endpoints: Nivolumab + ipilimumab vs chemotherapy OS in PD-L1 selected populations PFS in TMB-selected populations
34 PFS (%) Co-primary Endpoint: PFS With Nivolumab + Ipilimumab vs Chemotherapy in Patients With High TMB ( 10 mut/mb) 100 Nivo + ipi (n = 139) Chemo (n = 160) RR Median PFS, b mo HR c 97.5% CI 45.3% , 0.81 P = % y PFS = 43% Nivolumab + ipilimumab 20 1-y PFS = 13% No. at risk Chemotherapy Months Nivo + ipi Chemo PFS benefit was independent of PD-L1 and histology In patients with TMB <10 mut/mb treated with nivo + ipi vs chemo, the HR was 1.07 (95% CI: 0.84, 1.35) d Hellman, AACR 2017
35 PFS With Nivolumab + Chemotherapy and Nivolumab + Ipilimumab by TMB Status Borghaei H, ASCO 2018
36 CM 227: PROs Results PRO measures assessed LCSS: ASBI; 3-IGI EQ-5D (3-level): VAS; UI Mean (95% CI) change from baseline MID Nivo + ipi Chemo LCSS ASBI MID Worse Better Mean (95% CI) change from baseline MID Nivo + ipi Chemo LCSS Fatigue MID Worse Better Mean (95% CI) change from baseline MID Nivo + ipi Chemo LCSS Dyspnea MID Worse Better Weeks n n Weeks n n Weeks n n Proportion of patients with symptom deterioration on treatment or followup by week 12 Disease-related deterioration rate by 12 weeks, % Absolute risk reduction, % (95% CI) 12.7 ( ) 22.3 c 35.0 d n/n 31/139 56/160 Nivo + ipi Chemo Probability of not worsening n Nivo + ipi (n = 139) Chemo (n = 160) Median TTD, mo e NR 6.2 HR 95% CI Months Nivo + ipi n Chemo 5 3 Time to first disease-related deterioration on treatment Brahmer, WCLC 2018
37 B-F1RST Kim, ESMO 2018
38 B-F1RST: Feasibility Kim, ESMO 2018
39 Kim, ESMO 2018 B-F1RST PFS OS
40 Burning Questions for Tomorrow 1. What treatment according to PD-L1 expression level? 2. There is a role for the quadruplet with bevacizumab? 3. Patient characteristics: age and PS? Toxicity? 4. Concomitant treatment: steroids and antibiotics?
41 1. What treatment according to PD-L1 expression level?
42 Besse, ESMO 2018 PD-L1 <50%: ICI + Chemo vs Chemo? CT + immuno - OS PDL1 negative - OS
43 PD-L1 50%: Pembro w/o Chemo? OS Treatment Options (no comparative RCTs): PEMBRO PEMBRO + Chemotherapy PFS No significant Interaction in OS Significant Interaction in PFS and ORR in favour of the combo strategy ORR Clinical decision should be individualized considering patients overall health and comorbidities, disease characteristics (i.e. is rapid response required?), and safety concerns. Pilotto S et al, Semin Oncol 2018 [in press]
44 2. There is a role for the quadruplet with bevacizumab? Besse, ESMO 2018
45 Liver Metastasis
46 Liver Metastasis
47 3. Patient characteristics: immunological age?
48 3. Patient characteristics: PS?
49 Adverse events with IO single agent versus IO+CT combo IMPOWER IMPOWER
50 Safety Summary of Treatment-Related AEs: Nivo + Ipi could be less toxic than other combinations Nivolumab + chemotherapy (n = 172) Any grade Grade 3 4 Any grade Nivolumab + ipilimumab (n = 185) Grade 3 4 Chemotherapy (n = 183) Any grade Grade 3 4 Any TRAE, a % TRAE leading to discontinuation, b % Median number of doses received, n 8.5 for nivolumab (Q3W) 4 7 for chemo (Q3W) 8.0 for nivolumab (Q2W) 3.0 for ipilimumab (Q6W) 4 7 for chemo (Q3W) There were 4 treatment-related deaths in the nivolumab + chemo arm, 7 in both nivolumab + ipilimumab arms in Part 1, c and 6 in both chemo arms in Part 1 d Borghaei H et al. ASCO 2018
51 Arbour, JCO 2018 Fucà, WCLC Concomitant treatment: steroids?
52 4. Concomitant treatment: antibiotics? Routy, Science 2018 Multiple reports on n=1744 demonstrate the negative influence of ATB on immune checkpoint inhibitors. Shorter course of ATB 6 days vs 9 days might be safer [Gallio et al. WCLC 2018] Patients hospitalized or receiving IV ATB should be considered separately [Rubio et al. WCLC 2018] Citrulline may represent a surrogate marker of GI health [Leprieur et al. WCLC 2018]
53 Immuno alone? Immuno or chemo + immuno? Antiangiogenic? Patients characteristics? Age-PS? Histology? Oncogeneaddicted? Sequence? Steroids? Antibiotics? PD-L1 or TMB? Immunological profile Toxicity? Molecular background
54
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationIMMUNE CHECKPOINT BLOCKADE FOR NSCLC. Marina Chiara Garassino
IMMUNE CHECKPOINT BLOCKADE FOR NSCLC Marina Chiara Garassino Cells of the Immune System Innate immune system: Involving proteins (chemokines and cytokines) and cells, is considered to be the first line
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationStato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia Medica Ospedale S.Vincenzo, Taormina
I CONVEGNO REGIONALE SIFO MEETING DI PRIMAVERA IL FARMACISTA CLINICO E I NUOVI MODELLI DI CURA Taormina, 11/12/13 maggio 217 Stato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationESMO 2018 CONGRESS October 2018 Munich, Germany. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 218 CONGRESS 19 23 October 218 Munich, Germany Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationesmo.org ESMO IMMUNO-ONCOLOGY CONGRESS 2017
ESMO IMMUNO-ONCOLOGY CONGRESS 2017 Primary PFS and safety analyses of a randomised Phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationCarcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationFattori predittivi di efficacia ed interpretazione della risposta all immunoterapia. Dott. Matteo Brighenti Oncologia Cremona
Fattori predittivi di efficacia ed interpretazione della risposta all immunoterapia Dott. Matteo Brighenti Oncologia Cremona AREA DI RICERCA CLINICA EPIDEMIOLOGICA ONCOLOGIA CREMONA mos in 4 phase III
More informationLATEST DEVELOPMENT IN LUNG CANCER IMUNOTHERAPY & INSIGHTS TO THE DAILY CLINICAL PRACTICE
LATEST DEVELOPMENT IN LUNG CANCER IMUNOTHERAPY & INSIGHTS TO THE DAILY CLINICAL PRACTICE Solange Peters MD-PhD Head Medical Oncology and Thoracic Clinic Oncology Department Lausanne University Hospital
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationTable of Contents. Editorial Board: special issue
special issue ASCO 2018 Table of Contents S30 Preface S30 PD-(L)1 inhibition alone and in combination: recent insights into immunotherapy S35 Immune checkpoint blockade: determinants of treatment success
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer June 3, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer June 3, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationLead team presentation:
Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More information